Quantitative qRT-PCR and flow cytometry analysis results showed that UC-, BM, and AD-MSCs tested weak positive for CCR1 and less weak for CCR4 but not for CCR2, CCR3, and CCR5 with or without 10% FBS supplementation (Supplementary Figure S4A–E). This evidence concerns the gene CCR5 and Alzheimer disease.